Evidence map›Paper›PMID 37356446›Full record

ArticleLancet (London, England)2023

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.

GBD 2021 Diabetes Collaborators

Erratum issued 6 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 2,720 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,720citing papers in PubMed, 11 pooled it
1277.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06108388 unknown statusnot on this map

Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion in Type 2 Diabetes

TypeobservationalSponsorCanadian Medical and Surgical Knowledge Translation Research GroupRan2023 to 2026Enrolled90ConditionsDiabetes Mellitus, Type 2
NCT06769347 active not recruitingnot on this mapstarted 2025, after this paper: background citation

Circulating Vascular Regenerative Cell Exhaustion in Individuals Without Type 2 Diabetes Who Are of South Asian or European Origins

TypeobservationalSponsorCanadian Medical and Surgical Knowledge Translation Research GroupRan2025 to 2028Enrolled120ConditionsCardiovascular Diseases Risk
NCT07175701 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Ultra-processed Food Reduction Intervention on Postprandial Glucose and Glycemic Variability in Korean Young Adults: Study Protocol for the ULTRA-CGM Randomized Controlled Trial

TypeinterventionalSponsorKorea UniversityRan2025 to 2026Enrolled50ConditionsPostprandial Glucose, Glucose Levels, HyperglycemiasArms40-minute one-on-one dietary counseling and nutrition education aimed at reducing ultra-processed food consumption, Standard dietary counseling and nutrition education based on national guidelines
NCT07375719 completednot on this mapstarted 2024, after this paper: background citation

Nuclear Abnormalities in Gingival Epithelial Cells in Relation to Periodontal Disease Severity and Glycemic Control

TypeobservationalSponsorÇankırı Karatekin UniversityRan2024 to 2026Enrolled95ConditionsDiabetes (DM), Periodontitis, Periodontitis (Stage 3), Micronuclei Count
NCT07548372 narecruitingnot on this mapstarted 2026, after this paper: background citation

Supporting Primary Care Adoption, Resources, and Knowledge for Continuous Glucose Monitoring

TypeinterventionalSponsorMontefiore Medical CenterRan2026 to 2028Enrolled20,000ConditionsDiabetes MellitusArmsEnhanced CGM Interventions, Standard of Care
NCT07602023 recruitingnot on this mapstarted 2024, after this paper: background citation

Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.

TypeobservationalSponsorAngelina PassaroRan2024 to 2028Enrolled150ConditionsPrediabetes / Type 2 DiabetesArmsOral Fat Load Test
3 · Its place in the literature

Who cites it

2,720 citing papers in PubMed, 11 syntheses or guidelines pooled it, 3,876 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Gestational Diabetes Mellitus and Adverse Maternal and Neonatal Health Outcomes: an Umbrella review of Meta-Analyses.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

2,660 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

GBD 2021 Diabetes Collaborators
University of Washington · US

Funding

Role of mid- and late-life risk factors in social inequalities in Alzheimer's Disease and Related DementiasRF1AG062553 · NIA · INSERM PARIS 5 · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2019 to 2019
$1.5M
MASALA-2G: Multi-level Assessment of the South Asian Life-course of Atherosclerosis (2nd Generation Offspring Study)K23HL157766 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHAH, NILAY S. · 2021 to 2025
$873k
DBT-Wellcome Trust India Alliance IA/CPHE/17/1/503345Medical Research Council MR/M015084/1Medical Research Council MR/R024227/1NHLBI NIH HHS K23 HL157766NIA NIH HHS RF1 AG062553NIOSH CDC HHS T42 OH008421Wellcome Trust
6 · The paper itself

Abstract

backgroundDiabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050.

methodsEstimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively.

findingsIn 2021, there were 529 million (95% uncertainty interval [UI] 500-564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8-6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7-9·9]) and, at the regional level, in Oceania (12·3% [11·5-13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1-79·5) in individuals aged 75-79 years. Total diabetes prevalence-especially among older adults-primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1-96·8) of diabetes cases and 95·4% (94·9-95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5-71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5-30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22-1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1-17·6) in north Africa and the Middle East and 11·3% (10·8-11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%.

interpretationDiabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers.

fundingBill & Melinda Gates Foundation.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AgedBayes TheoremFemaleGlobal Burden of DiseaseGlobal HealthHumansLife ExpectancyMalePrevalenceQuality-Adjusted Life YearsRisk Factors

Identifiers

PMID37356446
PMCPMC10364581
OpenAlexW4381799391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.